AstraZeneca is driven by a diversified portfolio, robust R&D, and strong FCF, despite a current valuation that is slightly ...

April 2 (Reuters) - AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant ...

A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs. The ...

AstraZeneca PLC (NYSE:AZN) is one of Goldman Sachs top healthcare stocks. On March 9, AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo secured Priority Review in the US for Enhertu, their candidate drug ...

AstraZeneca PLC (NYSE:AZN) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 16, 2026, AstraZeneca ...

WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in ...

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...

AstraZeneca named a new CFO, and its current CFO will become its chief strategy officer and the CEO of Alexion, the drugmaker announced June 4. In December 2020, AstraZeneca said it was acquiring ...

AstraZeneca shares rallied on Wednesday after the U.K.-based pharmaceuticals giant and its Japanese partner said the Food and Drug Administration was reviewing one of its drugs to treat breast cancer.

People who receive AstraZeneca’s COVID-19 vaccine have a slightly increased risk of bleeding problems, according to a study published June 9 in Nature Medicine. Researchers observed adults in Scotland ...